Validea's guru fundamental report ranks Boston Scientific (BSX) highest among its 22 guru strategies under the Peter Lynch P/E/Growth Investor model, assigning a 69% score for the large-cap medical-equipment firm; the model flags passes on the P/E-to-growth ratio, inventory-to-sales, EPS growth and total debt/equity, a failure on the sales-and-P/E test, and neutral readings for free cash flow and net cash. A 69% rating indicates moderate alignment with Lynch’s criteria—reflecting reasonable earnings growth and balance-sheet strength but falling short of the 80%+ threshold the model typically treats as a stock of interest.
Validea’s guru fundamental report ranks Boston Scientific (BSX) highest among its 22 guru strategies under the Peter Lynch P/E/Growth Investor model, assigning a 69% score for the large-cap Medical Equipment & Supplies company; the model prioritizes reasonable price relative to earnings growth and balance-sheet strength. The report explicitly records a PASS on the P/E/Growth ratio, inventory-to-sales, EPS growth rate and total debt/equity, a FAIL on the sales-and-P/E test, and NEUTRAL readings for free cash flow and net cash position. A 69% rating is below Validea’s 80% interest threshold and well short of 90% for strong interest, indicating moderate alignment with Lynch’s criteria rather than a clear buy signal. Market signals are mildly positive (sentiment score 0.25) with low market-impact (0.15), implying limited near-term market reaction; the combination of confirmed EPS growth and manageable leverage supports the company’s fundamental case, while the failed sales/P·E test and neutral cash metrics are the primary valuation and liquidity risks to monitor.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
